[{"ID":"25493_36_NCT03817242","TOPIC_YEAR":2022,"RESPONSE":"O","PROBA":1.0},{"ID":"21297_30_NCT03676790","TOPIC_YEAR":2022,"RESPONSE":"Osteoarthritis levels 2 - 4 according to Kellgren-Lawrence grade12, but the patient is only at level 3.","PROBA":0.9830169794},{"ID":"18839_27_NCT02018497","TOPIC_YEAR":2022,"RESPONSE":"(Lyme disease is not related to essential hypotension or allostasis)","PROBA":0.9442156404},{"ID":"6808_15_NCT02191839","TOPIC_YEAR":2021,"RESPONSE":"O","PROBA":0.9997813702},{"ID":"33704_71_NCT02620670","TOPIC_YEAR":2021,"RESPONSE":"O","PROBA":1.0},{"ID":"10105_15_NCT01476995","TOPIC_YEAR":2022,"RESPONSE":"O","PROBA":1.0},{"ID":"19262_40_NCT04415619","TOPIC_YEAR":2021,"RESPONSE":"O","PROBA":1.0},{"ID":"7843_17_NCT01241708","TOPIC_YEAR":2021,"RESPONSE":"O: not relevant for clinical trial","PROBA":0.9972446495},{"ID":"30851_65_NCT03379792","TOPIC_YEAR":2021,"RESPONSE":"O: not relevant for clinical trial","PROBA":0.9237833321},{"ID":"33896_71_NCT04186780","TOPIC_YEAR":2021,"RESPONSE":"O","PROBA":1.0},{"ID":"25307_36_NCT02403492","TOPIC_YEAR":2022,"RESPONSE":"O","PROBA":1.0},{"ID":"8274_12_NCT01620645","TOPIC_YEAR":2022,"RESPONSE":"O","PROBA":1.0},{"ID":"21104_30_NCT02211898","TOPIC_YEAR":2022,"RESPONSE":"O","PROBA":0.9999998212},{"ID":"17163_36_NCT02582424","TOPIC_YEAR":2021,"RESPONSE":"O: not eligible","PROBA":0.9999935201},{"ID":"5297_12_NCT01338077","TOPIC_YEAR":2021,"RESPONSE":"O: not eligible","PROBA":0.9974870767},{"ID":"8510_12_NCT03237221","TOPIC_YEAR":2022,"RESPONSE":"O","PROBA":0.9999664724},{"ID":"13942_30_NCT00349635","TOPIC_YEAR":2021,"RESPONSE":"O: not relevant for clinical trial","PROBA":0.9136333482},{"ID":"10074_15_NCT01168908","TOPIC_YEAR":2022,"RESPONSE":"O: not relevant for clinical trial","PROBA":0.9986187021},{"ID":"6742_15_NCT01707524","TOPIC_YEAR":2021,"RESPONSE":"(age > 70)","PROBA":0.9981878549},{"ID":"16879_36_NCT00273572","TOPIC_YEAR":2021,"RESPONSE":"Obesity (BMI: 30-40 kg\/squared meter)","PROBA":0.9945905209},{"ID":"25339_36_NCT02622516","TOPIC_YEAR":2022,"RESPONSE":"O","PROBA":0.9999917746},{"ID":"16891_36_NCT00349635","TOPIC_YEAR":2021,"RESPONSE":"O","PROBA":0.9908678532},{"ID":"7989_17_NCT02849444","TOPIC_YEAR":2021,"RESPONSE":"O","PROBA":0.9866203666},{"ID":"21427_30_NCT04472702","TOPIC_YEAR":2022,"RESPONSE":"Osteoarthritis","PROBA":0.9986952373},{"ID":"30836_65_NCT03198962","TOPIC_YEAR":2021,"RESPONSE":"O","PROBA":0.9999999702},{"ID":"8523_12_NCT03274544","TOPIC_YEAR":2022,"RESPONSE":"O","PROBA":0.9995585084},{"ID":"10090_15_NCT01380964","TOPIC_YEAR":2022,"RESPONSE":"O","PROBA":0.9995225668},{"ID":"19105_40_NCT02802384","TOPIC_YEAR":2021,"RESPONSE":"O: eligible","PROBA":0.9999834696},{"ID":"21134_30_NCT02484508","TOPIC_YEAR":2022,"RESPONSE":"O","PROBA":0.9239838421},{"ID":"8394_12_NCT02385812","TOPIC_YEAR":2022,"RESPONSE":"O","PROBA":0.9942459464},{"ID":"12416_27_NCT00709228","TOPIC_YEAR":2021,"RESPONSE":"O: not relevant for clinical trial","PROBA":0.9879790015},{"ID":"17094_36_NCT02018497","TOPIC_YEAR":2021,"RESPONSE":"(the patient is not hypertensive)","PROBA":0.9987990499},{"ID":"14267_30_NCT04426435","TOPIC_YEAR":2021,"RESPONSE":"O","PROBA":1.0},{"ID":"5445_12_NCT03286088","TOPIC_YEAR":2021,"RESPONSE":"O","PROBA":1.0},{"ID":"33664_71_NCT02364128","TOPIC_YEAR":2021,"RESPONSE":"O","PROBA":1.0},{"ID":"5540_12_NCT04415138","TOPIC_YEAR":2021,"RESPONSE":"O: oncological patient","PROBA":0.8609283194},{"ID":"25104_53_NCT01583621","TOPIC_YEAR":2021,"RESPONSE":"O: not relevant for clinical trial","PROBA":0.984196451},{"ID":"21111_30_NCT02295189","TOPIC_YEAR":2022,"RESPONSE":"Osteoarthritis is a disabling disease of the joint spaces and has a high impact on society due to the amount of people who are affected by the disease. Nonoperative management is a mainstay of therapy in most patients. Ketorolac tromethamine and triamcinolone acetonide intra-articular knee injections will be compared in a prospective, double-blinded, randomized trial in subjects with knee osteoarthritis. Subjects will be enrolled from the Orthopaedics Clinic based on inclusion and exclusion criteria.","PROBA":0.9997063427},{"ID":"8046_17_NCT03678259","TOPIC_YEAR":2021,"RESPONSE":"O","PROBA":0.9999965131},{"ID":"14251_30_NCT04236232","TOPIC_YEAR":2021,"RESPONSE":"O: not relevant for clinical trial","PROBA":0.9999092486},{"ID":"17047_36_NCT01624155","TOPIC_YEAR":2021,"RESPONSE":"O: not eligible","PROBA":0.9257810627},{"ID":"33700_71_NCT02582424","TOPIC_YEAR":2021,"RESPONSE":"O: not eligible","PROBA":0.9999990038},{"ID":"33430_71_NCT00473655","TOPIC_YEAR":2021,"RESPONSE":"O","PROBA":1.0},{"ID":"7047_15_NCT04344353","TOPIC_YEAR":2021,"RESPONSE":"O","PROBA":1.0},{"ID":"33644_71_NCT02153021","TOPIC_YEAR":2021,"RESPONSE":"O","PROBA":0.9999929965},{"ID":"8659_12_NCT04259736","TOPIC_YEAR":2022,"RESPONSE":"O","PROBA":0.9999395609},{"ID":"25463_53_NCT04812509","TOPIC_YEAR":2021,"RESPONSE":"O","PROBA":1.0},{"ID":"17170_36_NCT02620670","TOPIC_YEAR":2021,"RESPONSE":"O","PROBA":0.8886499405},{"ID":"12796_27_NCT04301882","TOPIC_YEAR":2021,"RESPONSE":"O","PROBA":0.9999959171},{"ID":"21322_30_NCT03853551","TOPIC_YEAR":2022,"RESPONSE":"O","PROBA":1.0}]
